306 related articles for article (PubMed ID: 18410960)
41. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
42. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
43. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
44. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
[TBL] [Abstract][Full Text] [Related]
45. Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
BMC Pulm Med; 2019 Aug; 19(1):158. PubMed ID: 31438916
[TBL] [Abstract][Full Text] [Related]
46. IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis.
Wilson TM; Maric I; Shukla J; Brown M; Santos C; Simakova O; Khoury P; Fay MP; Kozhich A; Kolbeck R; Metcalfe DD; Klion AD
J Allergy Clin Immunol; 2011 Nov; 128(5):1086-92.e1-3. PubMed ID: 21762978
[TBL] [Abstract][Full Text] [Related]
47. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Varricchi G; Bagnasco D; Ferrando M; Puggioni F; Passalacqua G; Canonica GW
Ther Adv Respir Dis; 2017 Jan; 11(1):40-45. PubMed ID: 27856823
[TBL] [Abstract][Full Text] [Related]
48. Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C chemokines.
Shahabuddin S; Ponath P; Schleimer RP
J Immunol; 2000 Apr; 164(7):3847-54. PubMed ID: 10725746
[TBL] [Abstract][Full Text] [Related]
49. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma.
Stirling RG; van Rensen EL; Barnes PJ; Chung KF
Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 1):1403-9. PubMed ID: 11704586
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
[TBL] [Abstract][Full Text] [Related]
53. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
[TBL] [Abstract][Full Text] [Related]
54. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
Heinisch IV; Bizer C; Volgger W; Simon HU
J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
[TBL] [Abstract][Full Text] [Related]
55. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
56. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
57. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
[TBL] [Abstract][Full Text] [Related]
58. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
Gevaert P; Van Bruaene N; Cattaert T; Van Steen K; Van Zele T; Acke F; De Ruyck N; Blomme K; Sousa AR; Marshall RP; Bachert C
J Allergy Clin Immunol; 2011 Nov; 128(5):989-95.e1-8. PubMed ID: 21958585
[TBL] [Abstract][Full Text] [Related]
59. Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia.
Khoury P; Makiya MA; Rahim R; Bowman A; Espinoza D; Schiffenbauer A; Koch M; Anderson C; Constantine G; Maric I; Sun X; Pittaluga S; Brown T; Ware JM; Wetzler L; Fay MP; Klion AD
J Allergy Clin Immunol; 2024 Mar; 153(3):821-830.e6. PubMed ID: 37951310
[TBL] [Abstract][Full Text] [Related]
60. Interleukin 5 activity in sera from patients with eosinophilia.
Enokihara H; Kajitani H; Nagashima S; Tsunogake S; Takano N; Saito K; Furusawa S; Shishido H; Hitoshi Y; Takatsu K
Br J Haematol; 1990 Aug; 75(4):458-62. PubMed ID: 2206996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
